Adeoye Olukotun Sells 2,000 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Adeoye Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $87.11 on Friday. The company’s 50 day simple moving average is $82.84 and its 200-day simple moving average is $72.87. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $20.44 and a 1 year high of $95.49. The company has a market capitalization of $12.27 billion, a price-to-earnings ratio of -38.72 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The company had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. During the same period in the previous year, the business posted ($1.26) EPS. The business’s revenue for the quarter was up 171.0% on a year-over-year basis. As a group, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current year.

Institutional Trading of Arrowhead Pharmaceuticals

A number of large investors have recently made changes to their positions in ARWR. Tsfg LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. Optiver Holding B.V. grew its stake in shares of Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals in the third quarter valued at $29,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on ARWR. Chardan Capital boosted their price objective on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Morgan Stanley lifted their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. HC Wainwright boosted their price target on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $97.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.